PBH Relative Valuation
PBH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PBH is overvalued; if below, it's undervalued.
Historical Valuation
Prestige Consumer Healthcare Inc (PBH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 12.80 is considered Undervalued compared with the five-year average of 14.36. The fair price of Prestige Consumer Healthcare Inc (PBH) is between 64.99 to 77.81 according to relative valuation methord. Compared to the current price of 60.97 USD , Prestige Consumer Healthcare Inc is Undervalued By 6.19%.
Relative Value
Fair Zone
64.99-77.81
Current Price：60.97
6.19%
Undervalued
12.80
PE
1Y
3Y
5Y
Trailing
Forward
10.26
EV/EBITDA
Prestige Consumer Healthcare Inc. (PBH) has a current EV/EBITDA of 10.26. The 5-year average EV/EBITDA is 11.59. The thresholds are as follows: Strongly Undervalued below 9.83, Undervalued between 9.83 and 10.71, Fairly Valued between 12.47 and 10.71, Overvalued between 12.47 and 13.36, and Strongly Overvalued above 13.36. The current Forward EV/EBITDA of 10.26 falls within the Undervalued range.
11.16
EV/EBIT
Prestige Consumer Healthcare Inc. (PBH) has a current EV/EBIT of 11.16. The 5-year average EV/EBIT is 12.74. The thresholds are as follows: Strongly Undervalued below 10.84, Undervalued between 10.84 and 11.79, Fairly Valued between 13.69 and 11.79, Overvalued between 13.69 and 14.64, and Strongly Overvalued above 14.64. The current Forward EV/EBIT of 11.16 falls within the Undervalued range.
2.60
PS
Prestige Consumer Healthcare Inc. (PBH) has a current PS of 2.60. The 5-year average PS is 2.76. The thresholds are as follows: Strongly Undervalued below 1.94, Undervalued between 1.94 and 2.35, Fairly Valued between 3.18 and 2.35, Overvalued between 3.18 and 3.59, and Strongly Overvalued above 3.59. The current Forward PS of 2.60 falls within the Historic Trend Line -Fairly Valued range.
10.03
P/OCF
Prestige Consumer Healthcare Inc. (PBH) has a current P/OCF of 10.03. The 5-year average P/OCF is 11.56. The thresholds are as follows: Strongly Undervalued below 8.30, Undervalued between 8.30 and 9.93, Fairly Valued between 13.19 and 9.93, Overvalued between 13.19 and 14.83, and Strongly Overvalued above 14.83. The current Forward P/OCF of 10.03 falls within the Historic Trend Line -Fairly Valued range.
10.77
P/FCF
Prestige Consumer Healthcare Inc. (PBH) has a current P/FCF of 10.77. The 5-year average P/FCF is 12.23. The thresholds are as follows: Strongly Undervalued below 9.09, Undervalued between 9.09 and 10.66, Fairly Valued between 13.79 and 10.66, Overvalued between 13.79 and 15.36, and Strongly Overvalued above 15.36. The current Forward P/FCF of 10.77 falls within the Historic Trend Line -Fairly Valued range.
Prestige Consumer Healthcare Inc (PBH) has a current Price-to-Book (P/B) ratio of 1.58. Compared to its 3-year average P/B ratio of 2.03 , the current P/B ratio is approximately -22.05% higher. Relative to its 5-year average P/B ratio of 1.94, the current P/B ratio is about -18.24% higher. Prestige Consumer Healthcare Inc (PBH) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 7.10%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 7.76% , the current FCF yield is about -100.00% lower.
1.58
P/B
Median3y
2.03
Median5y
1.94
8.81
FCF Yield
Median3y
7.10
Median5y
7.76
Competitors Valuation Multiple
The average P/S ratio for PBH's competitors is , providing a benchmark for relative valuation. Prestige Consumer Healthcare Inc Corp (PBH) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -3.41%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PBH decreased by 23.09% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from 14.87 to 14.86.
The secondary factor is the Revenue Growth, contributed -3.41%to the performance.
Overall, the performance of PBH in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Prestige Consumer Healthcare Inc (PBH) currently overvalued or undervalued?
What is Prestige Consumer Healthcare Inc (PBH) fair value?
How does PBH's valuation metrics compare to the industry average?
What is the current P/B ratio for Prestige Consumer Healthcare Inc (PBH) as of Dec 05 2025?
What is the current FCF Yield for Prestige Consumer Healthcare Inc (PBH) as of Dec 05 2025?
What is the current Forward P/E ratio for Prestige Consumer Healthcare Inc (PBH) as of Dec 05 2025?